Do We Really Need New Trials on Fulvestrant in Prostate Cancer?

Féchon, Aude; Droz, Jean‐Pierre

doi:10.1159/000271605

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, an in vitro study performed using LNCaP PCa cells suggested that fulvestrant could inhibit AR transcripts, decreasing the response to androgens [ 193 ]. Based on these premises, the drug was tested in clinical trials in men affected by androgen-independent PCa, with contrasting results, animating the debate about its real benefits [ 195 , 195 , 217 , 222 , 223 ]. Interestingly, encouraging data came from the combinatorial use of fulvestrant and immunotherapy, although in the context of breast cancer [ 224 , 225 , 226 , 227 ].…”

Section: Molecules Targeting Nuclear Estrogen Receptorsmentioning

confidence: 99%

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

Belluti,

Imbriano,

Casarini

2023

Cancers

View full text Add to dashboard Cite

Estrogens are almost ubiquitous steroid hormones that are essential for development, metabolism, and reproduction. They exert both genomic and non-genomic action through two nuclear receptors (ERα and ERβ), which are transcription factors with disregulated functions and/or expression in pathological processes. In the 1990s, the discovery of an additional membrane estrogen G-protein-coupled receptor augmented the complexity of this picture. Increasing evidence elucidating the specific molecular mechanisms of action and opposing effects of ERα and Erβ was reported in the context of prostate cancer treatment, where these issues are increasingly investigated. Although new approaches improved the efficacy of clinical therapies thanks to the development of new molecules targeting specifically estrogen receptors and used in combination with immunotherapy, more efforts are needed to overcome the main drawbacks, and resistance events will be a challenge in the coming years. This review summarizes the state-of-the-art on ERα and ERβ mechanisms of action in prostate cancer and promising future therapies.

show abstract

Section: Molecules Targeting Nuclear Estrogen Receptorsmentioning

confidence: 99%

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

Belluti,

Imbriano,

Casarini

2023

Cancers

View full text Add to dashboard Cite

show abstract

Postoperative Follow-Up for Patients with Non-Small Cell Lung Cancer

Nakamura

Kurishima²,

Kobayashi³

et al. 2010

Onkologie

View full text Add to dashboard Cite

Background: It is unclear whether postoperative follow-up by thoracic surgeons or chest physicians for non-small cell lung cancer (NSCLC) alters survival. Patients and Methods: The charts of 1,398 NSCLC patients, diagnosed between 1980 and 2008, were reviewed. Prognostic factors contained therein were evaluated using univariate and multivariate analyses. Patients were divided into 2 groups according to the doctor in charge of their postoperative follow-up: the thoracic surgeon group and the chest physician group. The doctors in charge of following up the patients were also analyzed for prognostic significance. Results: In the univariate and multivariate analyses, age 65 years or younger, female sex, early pathological stage, Charlson Index score of 0–1, absence of adjuvant therapy, and follow-up by a chest physician were significantly favorable prognostic factors. Exam-ined overall, NSCLC patients in the chest physician group had longer survival than those in the thoracic surgeon group. The difference in survival of patients with advanced disease was also statistically significant between these 2 groups. Conclusions: Our results indicate that early detection of asymptomatic disease by regular follow-up including chest computed tomography scan may improve the chance of treatment with curative intent and thus may increase survival, irrespective of the doctor in charge of follow-up.

show abstract

Do We Really Need New Trials on Fulvestrant in Prostate Cancer?

Cited by 2 publications

References 19 publications

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

Postoperative Follow-Up for Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About